The global wearable injectors market is projected to reach USD 11.5 billion by 2026 from USD 7.2 billion in 2021, at a CAGR of 9.9% during the forecast period. Growth in this market is mainly driven by factors such as the shift of healthcare delivery toward homecare due to COVID-19, advantages of wearable injectors in the administration of various drugs, the rising prevalence of chronic diseases (such as cancer, diabetes, and CVD), favorable reimbursement scenario in major markets, and technological advancements in injector devices. However, the preference for alternative drug delivery modes, high costs, and a poor reimbursement structure in developing countries are expected to limit the adoption of wearable injectors to a certain extent.
The global wearable injectors market are Ypsomed(Switzerland), Amgen(California), Subcuject(Denmark), Enable Injections(Ohio), Medtronic Plc(Ireland), Insulet Corporation(US), United Therapeutics Corp (Us), CeQur SA(Switzerland), Sensile Medical(Switzerland), ATS Automation(Canada), West Pharmaceutical Services, Inc(US), Tandem Diabetes Care(US), Valeritas(US), Sonceboz(Switzerland), Noble(US), Elcam Drug Delivery Device(Israel), Bespak (UK), Stevanato Group(Italy), Sorrel Medical(Israel), Weibel CDS AG(Switzerland) and Neuma(US). These companies adopted strategies such as acquisitions, partnerships, expansions, and product launches to enhance their presence in the Wearable injectors market.
To know about the assumptions considered for the study download the pdf brochure
Amgen is a biotechnology company engaged in the discovery, development, manufacture, and marketing of innovative human therapeutics. The company operates through one business segment —Human Therapeutics. The company develops medicine in six focused therapeutic areas, namely, oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. Amgen operates in approximately 100 countries. The company offers wearable injector solutions for the treatment of neutropenia in cancer patients and the treatment of hyperlipidemia.
Medtronic is a medical technology company, which develops, manufactures, and markets a wide range of medical devices, therapies, and services for the treatment of conditions, such as heart diseases, spinal conditions, neurological disorders, vascular diseases, orthopedic disorders, and diabetes. The company operates through four major business segments—Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The company offers wearable injectors under its brand—Minimed—through its Diabetes Group segment.
Related Reports:
Wearable Injectors Market by Product Type(On-Body and Off-Body), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases), Technology(Spring-based, Motor Driven, Rotary Pump, Expanding Battery), Care Setting (Hospitals) - Global Forecast to 2026
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE